Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Sermorelin vs Somatrogon (Ngenla)
An educational, source-based comparison of Sermorelin and Somatrogon (Ngenla) — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Long-acting recombinant human growth hormone for pediatric GH deficiency — weekly dosing.
A long-acting recombinant fusion protein of human growth hormone with three copies of the C-terminal peptide (CTP) of hCG beta-subunit, extending half-life and enabling once-weekly subcutaneous dosing instead of daily.
- Pediatric growth hormone deficiency
- • FDA-approved June 2023.
- • Same class warnings as daily GH (intracranial hypertension, glucose effects, scoliosis progression).
- • Injection-site reactions common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
| Somatrogon (Ngenla) | Phase 3 weekly somatrogon vs daily somatropin in children with GHD | JCEM | 2022 | Non-inferior annual height velocity at 12 months with significantly better treatment-burden scores. |
Side-effect & safety grid
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
- FDA-approved June 2023.
- Same class warnings as daily GH (intracranial hypertension, glucose effects, scoliosis progression).
- Injection-site reactions common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Sermorelin vs Somatrogon (Ngenla) — Key differences
- Class: Sermorelin is classified as Growth Hormone Axis, while Somatrogon (Ngenla) is GH Analog · Endocrine.
- Primary research focus: Sermorelin — adult gh deficiency; Somatrogon (Ngenla) — pediatric growth hormone deficiency.
- Tag: Growth hormone vs FDA-Approved · Endocrine.